Floatz logo

AK105

MGMT-Unmethylated Glioblastoma

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical Schoolmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

353 Active assets in the MGMT-Unmethylated Glioblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

AK105 is also rated in:

hepatocellular carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
squamous cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →